Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6336 |
Amonafide
NSC308847,AS1413,氨萘非特,Nafidimide,AS1413,Quinamed |
Topoisomerase | DNA Damage/DNA Repair |
Amonafide (NSC-308847,AS1413) 是一种拓扑异构酶 II 的抑制剂和 DNA 的嵌入剂,通过拓扑异构酶 II 介导的反应产生蛋白质相关的 DNA 链断裂 | |||
T68985 |
Amonafide L-malate
|
||
Amonafide L-malate is the malate salt of amonafide, an imide derivative of naphthalic acid, with potential antineoplastic activity. Amonafide intercalates into DNA and inhibits topoisomerase II, resulting in DNA double-strand breaks (DSB) and inhibition of DNA replication and RNA synthesis. | |||
T70533 | Amonafide dihydrochloride | ||
Amonafide dihydrochloride is the dihydrochloride salt of amonafide, an imide derivative of naphthalic acid. Amonafide intercalates into DNA and inhibits topoisomerase II, resulting in protein-associated strand breaks and impaired DNA and RNA synthesis. | |||
T70531 |
CGP 55845
|
||
CGP 55845 is a potent, selective GABAB receptor antagonist (IC50 = 5 nM) that prevents agonist binding (pKi = 8.35) and inhibits GABA and glutamate release (pEC50 values are 8.08 and 7.85 respectively). | |||
T70222 | Ethonafide | ||
Ethonafide is an anthracene-containing derivative of amonafide that belongs to the azonafide series of anticancer agents. The lack of cross-resistance in multidrug-resistant cancer cell lines and the absence of a quinone and hydroquinone moiety make ethonafide a potentially less cardiotoxic replacement for existing anthracene-containing anticancer agents. Ethonafide was cytotoxic against three human prostate cancer cell lines at nanomolar concentrations. Ethonafide was found to be better tolerat... |